Assessment of Risks of Perinephric Fat Thickness to Adverse Renal Outcomes Post Donor Nephrectomy
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT06886087
- Status
- Recruiting
Conditions
- Hypertension
- Living Kidney Donation
- Nephrectomy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Accepted
Study Details
The goal of this observational study is to learn if PRAT thickness is a marker of visceral obesity and its influence on donors' kidney function and blood pressure in living kidney donors. Population includes male/female, 18 years and up, living kidney donors scheduled for nephrectomy within 6 months. The main area it aims to help in, is future care managing blood pressure and obesity in living kidney transplant donors. Primary Hypothesis: We hypothesize that Perirenal Fat Thickness (PRAT) may exhibit expansion, remodeling and inflammation that can negatively affect renal outcomes in LKDs. Researchers will compare PRAT morphology and inflammation in LKDs with low and high PRAT thickness. We will also correlate PRAT thickness with renal outcomes including vascular remodeling, at the time of donation and worsening hypertension and inadequately increased compensatory GFR of the LKD at 4-6 months post-donation. Participants will be separated into one of two groups depending on their PRAT measurement and asked to give samples of their blood, perinephric fat, and urine as research samples. Clinically we will abstract data up to 12 months prior and 6 months after their nephrectomy that includes laboratory findings, CT measurements, vitals, exam data, demographics, medical history and current medications.
Key Dates
- Start date
- Feb 10, 2025
- Status verified
- Feb 2026
- Primary completion
- Feb 10, 2027
- Completion
- Feb 10, 2028
Study Design
- Enrollment
- 100 participants (estimated)
Arms
- Arm: Non-ObeseParticipants with a BMI under 30
- Arm: ObeseParticipants with a BMI greater than or equal to 30
Primary Outcome Measure
Proinflammatory Macrophage infiltrations of Perinephric Fat for LKD [ Time Frame: 12 months ]
Central Contacts
- Jackie Reiter507-538-2224
- Maulik Lathiya, MBBS
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | Alexasandra Kukla, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
Related Studies
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Phoenix, Arizona
- Autonomic Regulation of Blood Pressure in Premature and Early Menopausal WomenRecruiting · University of Minnesota · Minneapolis, Minnesota
- Study of Disrupted Sleep in Somali AmericansRecruiting · Mayo Clinic · Rochester, Minnesota
- Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the FutureRecruiting · International Consortium of Circulatory Assist Clinicians · San Francisco, California